Halozyme’s primary technology is based on its proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) that degrades hyaluronan, or HA. HA is a glycosaminoglycan, a chain of natural sugars that is a component of normal tissue, such as skin and cartilage and can also accumulate around many solid cancerous tumors.

The effects of rHuPH20 are local and transient. By degrading HA, rHuPH20 facilitates the dispersion and absorption of other drugs and fluids that are injected under the skin.

HYLENEX® recombinant (hyaluronidase human injection) and ENHANZE® drug delivery technology are based on Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) that degrades hyaluronan.

Learn more about how we use the rHuPH20 enzyme to break down HA in the subcutaneous space.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok